Search Results - "Sukel, Myrthe P"

Refine Results
  1. 1
  2. 2
  3. 3

    Patterns of metachronous metastases after curative treatment of colorectal cancer by van Gestel, Yvette R.B.M, de Hingh, Ignace H.J.T, van Herk-Sukel, Myrthe P.P, van Erning, Felice N, Beerepoot, Laurens V, Wijsman, Jan H, Slooter, Gerrit D, Rutten, Harm J.T, Creemers, Geert-Jan M, Lemmens, Valery E.P.P

    Published in Cancer epidemiology (01-08-2014)
    “…Highlights • One fifth of operated colorectal cancer patients will develop metachronous metastases. • Colon and rectal cancer patients have different patterns…”
    Get full text
    Journal Article
  4. 4

    Pre- and post-diagnostic β-blocker use and lung cancer survival: A population-based cohort study by Weberpals, Janick, Jansen, Lina, Haefeli, Walter E., Hoffmeister, Michael, Wolkewitz, Martin, Herk-Sukel, Myrthe P. P. van, Vissers, Pauline A. J., Brenner, Hermann

    Published in Scientific reports (06-06-2017)
    “…Beta-blockers have been associated with decreased cancer mortality. However, evidence for lung cancer is sparse and reported beneficial effects might be based…”
    Get full text
    Journal Article
  5. 5
  6. 6

    A population‐based linked cohort of cancer and primary care data: A new source to study the management of cancer in primary care by Kuiper, Josephina G., Herk‐Sukel, Myrthe P. P., Lemmens, Valery E. P. P., Kuipers, Ernst J., Herings, Ron M. C.

    Published in European journal of cancer care (01-01-2022)
    “…Objective Insight into the management of cancer in the primary care setting is pivotal to improve early recognition and survival of cancer patients. Therefore,…”
    Get full text
    Journal Article
  7. 7
  8. 8
  9. 9

    Impact of cancer on adherence to glucose-lowering drug treatment in individuals with diabetes by Zanders, Marjolein M. J., Haak, Harm R., van Herk-Sukel, Myrthe P. P., van de Poll-Franse, Lonneke V., Johnson, Jeffrey A.

    Published in Diabetologia (01-05-2015)
    “…Aims/hypothesis Adherence to glucose-lowering drug (GLD) treatment regimens is crucial for metabolic control and improving prognosis. Because a diagnosis of…”
    Get full text
    Journal Article
  10. 10

    Incidence of cardiovascular disease up to 13 year after cancer diagnosis: A matched cohort study among 32 757 cancer survivors by Schoormans, Dounya, Vissers, Pauline A. J., Herk‐Sukel, Myrthe P. P., Denollet, Johan, Pedersen, Susanne S., Dalton, Susanne O., Rottmann, Nina, Poll‐Franse, Lonneke

    Published in Cancer medicine (Malden, MA) (01-10-2018)
    “…We examined the incidence of cardiovascular disease (CVD) among 32 757 cancer survivors and age‐, gender‐, and geographically matched cancer‐free controls…”
    Get full text
    Journal Article
  11. 11
  12. 12

    Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen by Binkhorst, Lisette, Mathijssen, Ron H. J., van Herk-Sukel, Myrthe P. P., Bannink, Marjolein, Jager, Agnes, Wiemer, Erik A. C., van Gelder, Teun

    Published in Breast cancer research and treatment (01-06-2013)
    “…Tamoxifen is a largely inactive pro-drug, requiring metabolism into its most important metabolite endoxifen. Since the cytochrome P450 (CYP) 2D6 enzyme is…”
    Get full text
    Journal Article
  13. 13
  14. 14

    Effect of Concomitant CYP2D6 Inhibitor Use and Tamoxifen Adherence on Breast Cancer Recurrence in Early-Stage Breast Cancer by DEZENTJE, Vincent O, VAN BLIJDERVEEN, Nico J. C, GELDERBLOM, Hans, PUTTER, Hein, VAN HERK-SUKEL, Myrthe P. P, CASPARIE, Mariel K, EGBERTS, Antoine C. G, NORTIER, Johan W. R, GUCHELAAR, Henk-Jan

    Published in Journal of clinical oncology (10-05-2010)
    “…The use of cytochrome P450 2D6-inhibiting drugs (CYP2D6 inhibitors) during tamoxifen treatment leads to a decrease in plasma concentration of endoxifen, the…”
    Get full text
    Journal Article
  15. 15
  16. 16
  17. 17
  18. 18

    Use and costs of oral anticancer agents in the Netherlands in the period 2000-2008 by Timmers, Lonneke, Beckeringh, Jan Jacob, van Herk-Sukel, Myrthe P. P., Boven, Epie, Hugtenburg, Jacqueline G.

    Published in Pharmacoepidemiology and drug safety (01-10-2012)
    “…ABSTRACT Purpose In recent years, the number of oral anticancer agents has increased substantially. Although these agents have quickly been incorporated in the…”
    Get full text
    Journal Article
  19. 19

    Record linkage for pharmacoepidemiological studies in cancer patients by van Herk-Sukel, Myrthe P. P., Lemmens, Valery E. P. P., van de Poll-Franse, Lonneke V., Herings, Ron M. C., Coebergh, Jan Willem W.

    Published in Pharmacoepidemiology and drug safety (01-01-2012)
    “…ABSTRACT Background An increasing need has developed for the post‐approval surveillance of (new) anti‐cancer drugs by means of pharmacoepidemiology and…”
    Get full text
    Journal Article
  20. 20

    Statin use and its effect on all‐cause mortality of melanoma patients: a population‐based Dutch cohort study by Livingstone, Elisabeth, Hollestein, Loes M., Herk‐Sukel, Myrthe P. P., Poll‐Franse, Lonneke, Joosse, Arjen, Schilling, Bastian, Nijsten, Tamar, Schadendorf, Dirk, Vries, Esther

    Published in Cancer medicine (Malden, MA) (01-10-2014)
    “…Preclinical data showed anticancer effects of statins in melanoma, but meta‐analyses could not demonstrate a reduced melanoma incidence in statin users. Rather…”
    Get full text
    Journal Article